Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.

× No keyword cloud information.

5 in total

Review 1. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

Authors: Matthias Scheffler; Paola Di Gion; Oxana Doroshyenko; Jürgen Wolf; Uwe Fuhr
Journal: Clin Pharmacokinet Date: 2011-06 Impact factor: 6.447

2. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.

Authors: Andrés F Cardona; Daniel Jaramillo-Velásquez; Alejandro Ruiz-Patiño; Carolina Polo; Enrique Jiménez; Fernando Hakim; Diego Gómez; Juan Fernando Ramón; Hernando Cifuentes; Juan Armando Mejía; Fernando Salguero; Camila Ordoñez; Álvaro Muñoz; Sonia Bermúdez; Nicolas Useche; Diego Pineda; Luisa Ricaurte; Zyanya Lucia Zatarain-Barrón; July Rodríguez; Jenny Avila; Leonardo Rojas; Elvira Jaller; Carolina Sotelo; Juan Esteban Garcia-Robledo; Nicolas Santoyo; Christian Rolfo; Rafael Rosell; Oscar Arrieta
Journal: J Neurooncol Date: 2021-09-09 Impact factor: 4.130

Review 3. Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors: Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal: CNS Drugs Date: 2015-11 Impact factor: 5.749

4. Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases.

Authors: Ling-Ling Kong; Lin-Lin Wang; Li-Gang Xing; Jin-Ming Yu
Journal: Chronic Dis Transl Med Date: 2017-12-12

Review 5. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.

Authors: A Katz; P Zalewski
Journal: Br J Cancer Date: 2003-12 Impact factor: 7.640

5 in total